The cognitive enhancer 'choline alfoscerate (choline products)' has expanded its presence in the prescription market. Choline products' growth slowed earlier this year but rebounded in Q3, further expanding the market size. Although a few companies withdrew from the market due to the risk of failing clinical re-evaluation, the prescription market continued sales boom.

According to the pharmaceutical market research firm UBIST on November 11, the outpatient prescription market for choline products totaled KRW 155.3 billion in Q3. It decreased by 0.9% compared to Q3 of last year but increased by 3.0% compared to the previous quarter.

Choline products' prescription sales recorded KRW 158.1 bill